TY - JOUR T1 - Real costs of end-of-life drugs JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 61 LP - 61 DO - 10.1136/dtb.2009.05.0019 VL - 47 IS - 6 A2 - , Y1 - 2009/06/01 UR - http://dtb.bmj.com/content/47/6/61.abstract N2 - In January 2009, the National Institute for Health and Clinical Excellence (NICE) began a policy for valuing the use of drugs for extending life in people with a short life-expectancy above treatments for other purposes. This development arose from concerns that NICE had been denying patients life-extending treatments because they were too expensive; such drugs exceeded the Institute's quality-adjusted life years (QALY) threshold of £20,000–£30,000. However, the new policy also … ER -